NO20054897L - Farmasoytisk preparat inneholdende platinakompleks som aktiv substans og fremgangsmate for fremstilling derav - Google Patents

Farmasoytisk preparat inneholdende platinakompleks som aktiv substans og fremgangsmate for fremstilling derav

Info

Publication number
NO20054897L
NO20054897L NO20054897A NO20054897A NO20054897L NO 20054897 L NO20054897 L NO 20054897L NO 20054897 A NO20054897 A NO 20054897A NO 20054897 A NO20054897 A NO 20054897A NO 20054897 L NO20054897 L NO 20054897L
Authority
NO
Norway
Prior art keywords
preparation
platinum complex
active substance
pharmaceutically acceptable
substance
Prior art date
Application number
NO20054897A
Other languages
English (en)
Inventor
Ales Franc
Peter Sova
Original Assignee
Pliva Lachema As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CZ2003915A external-priority patent/CZ296045B6/cs
Priority claimed from CZ2004235A external-priority patent/CZ295584B6/cs
Application filed by Pliva Lachema As filed Critical Pliva Lachema As
Publication of NO20054897L publication Critical patent/NO20054897L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives farmasøytiske preparater inneholdende platinakompleks med formel (I) som aktiv bestanddel, der A, A', B, B', X og X' har spesifikke betydninger, i blanding med minst en farmasøytisk akseptabel eksipient, der preparatet består av et granulat med partikler som er mindre enn 0,5 mm i størrelse, fremstilt ved våtgranulering av en blanding av platinakomplekset av tefravalent platina med formel (I) fiiktet med vann, minst ett nøyttalt sakkarid og minst ett nativt og/eller modifisert polysakkarid. Preparatet er inneholdt i en kapsel eUer en pose eUer er eventuelt presset tU tabletter mens overflaten av granulatet, kapselen eUer tablettene eventuelt er belagt med et sjikt av minst en farmasøytisk akseptabel substans som muhggjør enterosolvent oppløsning av den aktive substans kun i tarmene og/eller minst en farmasøytisk akseptabel substans som muliggjør konttollert fiigivning av den aktive substans. Det beskrives videre en fremgangsmåte for fremstilling av det farmasøytiske preparat.
NO20054897A 2003-03-31 2005-10-24 Farmasoytisk preparat inneholdende platinakompleks som aktiv substans og fremgangsmate for fremstilling derav NO20054897L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CZ2003915A CZ296045B6 (cs) 2003-03-31 2003-03-31 Farmaceutická kompozice obsahující jako účinnou látku komplex čtyřmocné platiny a způsob její výroby
CZ2004235A CZ295584B6 (cs) 2004-02-12 2004-02-12 Farmaceutická kompozice obsahující jako účinnou látku platinový komplex a způsob výroby této kompozice
PCT/CZ2004/000017 WO2004087126A1 (en) 2003-03-31 2004-03-30 Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof

Publications (1)

Publication Number Publication Date
NO20054897L true NO20054897L (no) 2005-10-24

Family

ID=33132424

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054897A NO20054897L (no) 2003-03-31 2005-10-24 Farmasoytisk preparat inneholdende platinakompleks som aktiv substans og fremgangsmate for fremstilling derav

Country Status (12)

Country Link
US (1) US20060063832A1 (no)
EP (1) EP1608358A1 (no)
JP (1) JP2006521300A (no)
BR (1) BRPI0408805A (no)
CA (1) CA2517120C (no)
HR (1) HRP20050902A2 (no)
MX (1) MXPA05010254A (no)
NO (1) NO20054897L (no)
RS (1) RS20050714A (no)
RU (1) RU2343913C2 (no)
UA (1) UA80872C2 (no)
WO (1) WO2004087126A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060446A1 (fr) 2001-01-29 2002-08-08 Shionogi & Co., Ltd. Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif
CZ295584B6 (cs) * 2004-02-12 2005-08-17 Pliva-Lachema A. S. Farmaceutická kompozice obsahující jako účinnou látku platinový komplex a způsob výroby této kompozice
CZ2004964A3 (cs) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
WO2009084216A1 (ja) * 2007-12-27 2009-07-09 Taiho Pharmaceutical Co., Ltd. 経口粉粒状抗腫瘍剤
US9393227B2 (en) * 2009-02-04 2016-07-19 The Brigham And Women's Hospital, Inc. Nanoscale platinum compounds and methods of use thereof
PT3386997T (pt) 2015-12-09 2021-11-04 Univ Wien Med Compostos de platina com funções de mono-maleimida para a terapêutica do cancro
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
JPS5970614A (ja) * 1982-10-14 1984-04-21 Asahi Chem Ind Co Ltd 微量主薬系湿式固形製剤方法
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5256653A (en) * 1987-02-19 1993-10-26 Henkel Kommanditgesellschaft Auf Aktien Pharmaceutical preparations containing platinum complexes/phosphonic acid liquid and processes for their use
US4946954A (en) * 1989-01-17 1990-08-07 Georgetown University Platinum pharmaceutical agents
FI905018A7 (fi) * 1989-10-17 1991-04-18 Bristol Myers Squibb Co Veteen ja liuottimeen liukenevat aksiaaliset hydroksi- ja mono- ja di-karboksyylihappojohdannaiset, joilla on korkea kasvainaktiivisuus
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
FR2729857B1 (fr) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
JPH10265380A (ja) * 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
CZ288912B6 (cs) * 1998-05-27 2001-09-12 Lachema, A. S. Komplex platiny v oxidačním čísle IV, způsob přípravy tohoto komplexu, tento komplex jako léčivo a farmaceutická kompozice tento komplex obsahující
KR100317473B1 (ko) * 1999-05-11 2001-12-22 이계호 신규의 백금(ｉｖ)착제 및 그 제조방법
JP2001347153A (ja) * 2000-06-12 2001-12-18 Asahi Kasei Corp 錠剤の製造方法

Also Published As

Publication number Publication date
WO2004087126A1 (en) 2004-10-14
AU2004226898A1 (en) 2004-10-14
BRPI0408805A (pt) 2006-03-28
RS20050714A (sr) 2008-04-04
RU2343913C2 (ru) 2009-01-20
JP2006521300A (ja) 2006-09-21
CA2517120C (en) 2012-09-18
RU2005133428A (ru) 2006-05-10
US20060063832A1 (en) 2006-03-23
HRP20050902A2 (en) 2005-12-31
CA2517120A1 (en) 2004-10-14
EP1608358A1 (en) 2005-12-28
MXPA05010254A (es) 2006-02-22
UA80872C2 (uk) 2007-11-12

Similar Documents

Publication Publication Date Title
KR100634253B1 (ko) 초강력 붕해제를 사용한 고속-용해 에파비렌즈 캡슐 또는정제 및 그의 제조 방법
DK168423B1 (da) Stabilt, presset farmaceutisk præparat og fremgangsmåde til fremstilling deraf.
NO20074092L (no) Tabletter for forbedret legemiddel dispersibilitet
MD4430C1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
RU2013120907A (ru) Мягкие жвачки, не содержащие крахмала
EA021570B1 (ru) Твердые композиции для лечения инфекции hcv (варианты)
CA2601955A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
KR102233757B1 (ko) 유기 화합물의 제제
WO2004108162A3 (en) Controlled release pharmaceutical composition
RU2008106220A (ru) Гастроретентивные композиции и способ их изготовления
BRPI0715634A2 (pt) composiÇÕes de imatinibe
NO20054897L (no) Farmasoytisk preparat inneholdende platinakompleks som aktiv substans og fremgangsmate for fremstilling derav
NO20022591L (no) Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre
CN114652811A (zh) 一种含有奈玛特韦和利托那韦的复方片剂
FR2819720B1 (fr) Nouveaux comprimes de fenofibrate
NZ560669A (en) Use of alkyl cellulose as controlled release matrix material in alcohol resistant dosage forms
JPS6396126A (ja) 安定化組成物
TW202002996A (zh) 含肽調配物
JP2010202579A (ja) アカルボースを含有する口腔内崩壊剤
KR20150115334A (ko) 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
CN101548958A (zh) 一种含有盐酸特比萘芬的分散片
CN104490802B (zh) 红景天苷肠溶片及其制备方法
CN106540265A (zh) 一种奥格列汀药物组合物及其制备方法
CN113908132A (zh) 一种阿戈美拉汀及其衍生物口腔贴片制剂及其制备方法
EA200900249A1 (ru) Фармацевтическая композиция и способ ее получения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application